Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18074482 | 0.85 | HTT (0.53) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL2665746 | 0.82 | TSHR (0.73) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL10117106 | 0.82 | KMT2A (0.49) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL8174236 | 0.80 | NAAA (0.67) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL24696326 | 0.79 | TSHR (0.57) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL13624736 | 0.78 | TSHR (0.41) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL14136411 | 0.76 | HTT (0.50) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL4760433 | 0.76 | HTT (0.50) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL7540866 | 0.76 | HTT (0.50) | HTTTSHRHPGDNAAAHCRTR1 | |
| SCHEMBL27503407 | 0.76 | HTT (0.50) | HTTTSHRHPGDNAAAHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | HTT 2804/4885TSHR 4347/4885KDM1A 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.